(lp0
S'Stock Beta Analysis: Sarepta Therapeutics, Inc.  The Oracle Examiner - Feb 16, 2017 While predicting the next move of Sarepta Therapeutics, Inc. , volatility is an important factor to look at.'
p1
aS"2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump Motley Fool - Mar 3, 2017 While Sarepta is well capitalized and will remain in growth mode, this company still has a long road ahead of it before it can hope to generate a profit.Vetr Advises Hold On Sarepta - BenzingaSarepta Therapeutics to Present Company Overview at the Cowen and Company 37th ... - Nasdaq"
p2
aS'Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference GlobeNewswire  - Mar 17, 2017 CAMBRIDGE, Mass., March 17, 2017  -- Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of&nbsp;...'
p3
aS"Sarepta Therapeutics Inc : Will Payors Reimburse Exondys 51? Smarter Analyst - Mar 10, 2017 Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc , as it appears that payors are still actively evaluating and reevaluating coverage of the company's muscular dystrophy drug Exondys 51.Payor Re-Evaluation On Exondys Positive For Sarepta - BenzingaSarepta  Exondys 51 Payor Discussions Progressing - Cowen - StreetInsider.com"
p4
aS"Sarepta  Q4 Loss Widens; Sales of Duchenne Drug Slow Nasdaq - Mar 1, 2017 Sarepta Therapeutics, Inc. SRPT reported wider-than-expected loss in the fourth quarter of 2016. Meanwhile, the biotech company's 2017 sales outlook fell largely short of expectations as the commercial launch of its only approved drug, Exondys 51, has&nbsp;...Sarepta Therapeutics Inc  Stock Heads Higher on Analyst Upgrade - Investorplace.comSarepta Therapeutics, Inc. | $SRPT Stock | Shares Fall On Poor Fourth Quarter ... - TickerTV News "
p5
aS"Why to Keeping Eye on New York Mortgage Trust, Inc. , Sarepta ... StockNewsJournal - 15 hours ago The average of this ratio is -2.57 for the industry and sector's best figure appears 13.02. Sarepta Therapeutics, Inc. , at its latest closing price of $28.93, it has a price-to-book ratio of 4.95, compared to an industry average at 10.15 ..."
p6
aS'Sarepta Therapeutics  to Sell PRV Voucher for $125M StreetInsider.com - Feb 21, 2017 Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher .Commit To Purchase Sarepta Therapeutics At $18, Earn 16.7% Using Options - Nasdaq'
p7
aS'Sarepta Therapeutics, Inc.  held by 16 SEC 13F Filers Post Analyst - 16 hours ago Sarepta Therapeutics, Inc.  reached 261.63% versus a 1-year low price of $8. The stock was last seen -4.99% lower, reaching at $28.93 on Mar. 21, 2017.Analysts Near-Term outlook: Sarepta Therapeutics , Rigel ... - The USA CommerceSarepta Therapeutics, Inc.  Shares Dip Under Moving Averages - Midway Monitor'
p8
aS'Sell-side Research Says Buy These Stocks: Sarepta Therapeutics, Inc. (NASDAQ ... Rives Journal - 15 hours ago Stock research firms currently have a positive stance on shares of Sarepta Therapeutics, Inc. . Analysts are projecting that the stock will reach $60.78 on a short term  basis.'
p9
aS'Is a Surprise Coming for Sarepta Therapeutics  This Earnings Season? Yahoo Finance - Feb 27, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics, Inc. SRPT may be one such company.'
p10
a.